Sullivan, Bruyette, Speros & Blaney’s AstraZeneca AZN Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$124K	Sell	1,245 -135	-10%	-$13.6K	0.01%	381
2020 Q4	$138K	Buy	1,380 +138	+11%	+$14.6K	0.01%	335
2020 Q3	$136K	Buy	1,242 +125	+11%	+$13.9K	0.01%	298
2020 Q2	$118K	Buy	+1,117	New	+$115K	0.01%	304
2020 Q1	–	Sell	-1,320	Closed	-$132K	–	302
2019 Q4	$132K	Buy	+1,320	New	+$124K	0.01%	305

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's AZN Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney reduced its AstraZeneca (AZN) stake by 9.8% in Q1 2021, selling an estimated $13.6K and leaving 1,245 shares worth $124K. The position accounts for 0.01% of the portfolio, ranked #381.

Sullivan, Bruyette, Speros & Blaney first reported a position in AZN in Q4 2019 and has held it in 5 quarters since. The position peaked at $138K in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Sullivan, Bruyette, Speros & Blaney held 1,245 shares of AstraZeneca worth $124K as of Q1 2021.
Sullivan, Bruyette, Speros & Blaney sold 135 AstraZeneca shares in Q1 2021, an estimated $13.6K.
AstraZeneca made up 0.01% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #381 holding.
Sullivan, Bruyette, Speros & Blaney first reported a position in AstraZeneca in Q4 2019 and has held it in 5 quarters since.
Sullivan, Bruyette, Speros & Blaney's AstraZeneca position peaked at $138K in Q4 2020.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.